Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 4(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04999098Phase 4Terminated

Echinaforce COVID-19 Shedding Study

Role: collaborator

NCT05002179Phase 4Completed

Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections

Role: collaborator

NCT04093518Phase 3Unknown

Estradiol as add-on to Antipsychotics

Role: collaborator

All 3 trials loaded